BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 8662951)

  • 41. Biotin-Chasing Assay to Evaluate uPAR Stability and Cleavage on the Surface of Cells.
    Leksa V; Schiller HB; Stockinger H
    Methods Mol Biol; 2018; 1731():39-47. PubMed ID: 29318541
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis].
    Kobayashi H
    Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):623-32. PubMed ID: 8808830
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Plasmin-dependent elimination of the growth-factor-like domain in urokinase causes its rapid cellular uptake and degradation.
    Poliakov A; Tkachuk V; Ovchinnikova T; Potapenko N; Bagryantsev S; Stepanova V
    Biochem J; 2001 May; 355(Pt 3):639-45. PubMed ID: 11311125
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes.
    Chavakis T; Kanse SM; Yutzy B; Lijnen HR; Preissner KT
    Blood; 1998 Apr; 91(7):2305-12. PubMed ID: 9516128
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Critical role of integrin alpha 5 beta 1 in urokinase (uPA)/urokinase receptor (uPAR, CD87) signaling.
    Tarui T; Andronicos N; Czekay RP; Mazar AP; Bdeir K; Parry GC; Kuo A; Loskutoff DJ; Cines DB; Takada Y
    J Biol Chem; 2003 Aug; 278(32):29863-72. PubMed ID: 12754207
    [TBL] [Abstract][Full Text] [Related]  

  • 46. THP-1 macrophage membrane-bound plasmin activity is up-regulated by transforming growth factor-beta 1 via increased expression of urokinase and the urokinase receptor.
    Falcone DJ; McCaffrey TA; Mathew J; McAdam K; Borth W
    J Cell Physiol; 1995 Aug; 164(2):334-43. PubMed ID: 7622580
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Synthesis, solution structure, and biological evaluation of urokinase type plasminogen activator (uPA)-derived receptor binding domain mimetics.
    Schmiedeberg N; Schmitt M; Rölz C; Truffault V; Sukopp M; Bürgle M; Wilhelm OG; Schmalix W; Magdolen V; Kessler H
    J Med Chem; 2002 Nov; 45(23):4984-94. PubMed ID: 12408709
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Urokinase-type Plasminogen Activator (uPA) Binding to the uPA Receptor (uPAR) Promotes Axonal Regeneration in the Central Nervous System.
    Merino P; Diaz A; Jeanneret V; Wu F; Torre E; Cheng L; Yepes M
    J Biol Chem; 2017 Feb; 292(7):2741-2753. PubMed ID: 27986809
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Structural basis of interaction between urokinase-type plasminogen activator and its receptor.
    Barinka C; Parry G; Callahan J; Shaw DE; Kuo A; Bdeir K; Cines DB; Mazar A; Lubkowski J
    J Mol Biol; 2006 Oct; 363(2):482-95. PubMed ID: 16979660
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Plasminogen-independent initiation of the pro-urokinase activation cascade in vivo. Activation of pro-urokinase by glandular kallikrein (mGK-6) in plasminogen-deficient mice.
    List K; Jensen ON; Bugge TH; Lund LR; Ploug M; Danø K; Behrendt N
    Biochemistry; 2000 Jan; 39(3):508-15. PubMed ID: 10642175
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Interaction of single-chain urokinase with its receptor induces the appearance and disappearance of binding epitopes within the resultant complex for other cell surface proteins.
    Higazi AA; Upson RH; Cohen RL; Manuppello J; Bognacki J; Henkin J; McCrae KR; Kounnas MZ; Strickland DK; Preissner KT; Lawler J; Cines DB
    Blood; 1996 Jul; 88(2):542-51. PubMed ID: 8695802
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Urokinase regulates vitronectin binding by controlling urokinase receptor oligomerization.
    Sidenius N; Andolfo A; Fesce R; Blasi F
    J Biol Chem; 2002 Aug; 277(31):27982-90. PubMed ID: 12034711
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Protease nexin-1-urokinase complexes are internalized and degraded through a mechanism that requires both urokinase receptor and alpha 2-macroglobulin receptor.
    Conese M; Olson D; Blasi F
    J Biol Chem; 1994 Jul; 269(27):17886-92. PubMed ID: 8027043
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dynamic assembly of the urokinase-type plasminogen activator signaling receptor complex determines the mitogenic activity of urokinase-type plasminogen activator.
    Jo M; Thomas KS; Marozkina N; Amin TJ; Silva CM; Parsons SJ; Gonias SL
    J Biol Chem; 2005 Apr; 280(17):17449-57. PubMed ID: 15728176
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor.
    Ploug M
    Curr Pharm Des; 2003; 9(19):1499-528. PubMed ID: 12871065
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Initiation of plasminogen activation on the surface of monocytes expressing the type II transmembrane serine protease matriptase.
    Kilpatrick LM; Harris RL; Owen KA; Bass R; Ghorayeb C; Bar-Or A; Ellis V
    Blood; 2006 Oct; 108(8):2616-23. PubMed ID: 16794252
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Urokinase induces expression of its own receptor in Beas2B lung epithelial cells.
    Shetty S; Idell S
    J Biol Chem; 2001 Jul; 276(27):24549-56. PubMed ID: 11342540
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network.
    Webb CP; Hose CD; Koochekpour S; Jeffers M; Oskarsson M; Sausville E; Monks A; Vande Woude GF
    Cancer Res; 2000 Jan; 60(2):342-9. PubMed ID: 10667586
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Regulation of single chain urokinase binding, internalization, and degradation by a plasminogen activator inhibitor 1-derived peptide.
    Zhang L; Strickland DK; Cines DB; Higazi AA
    J Biol Chem; 1997 Oct; 272(43):27053-7. PubMed ID: 9341144
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A soluble form of the urokinase plasminogen activator receptor (suPAR) can bind to hematopoietic cells.
    Mizukami IF; Todd RF
    J Leukoc Biol; 1998 Aug; 64(2):203-13. PubMed ID: 9715260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.